

# Johanne Silvain

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3305986/publications.pdf>

Version: 2024-02-01

138  
papers

9,488  
citations

66343

42  
h-index

38395

95  
g-index

149  
all docs

149  
docs citations

149  
times ranked

8312  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. <i>Lancet, The</i> , 2009, 373, 309-317.	13.7	864
2	Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. <i>New England Journal of Medicine</i> , 2012, 367, 2100-2109.	27.0	788
3	Pretreatment with Prasugrel in Non- $\sigma$ ST-Segment Elevation Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2013, 369, 999-1010.	27.0	539
4	Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2014, 371, 1016-1027.	27.0	538
5	Acute Myocardial Infarction. <i>Circulation</i> , 2017, 136, 1908-1919.	1.6	352
6	Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration. <i>Journal of the American College of Cardiology</i> , 2010, 56, 134-143.	2.8	348
7	Composition of Coronary Thrombus in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1359-1367.	2.8	329
8	Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. <i>Lancet, The</i> , 2016, 388, 2015-2022.	13.7	303
9	Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. <i>Lancet, The</i> , 2014, 384, 1577-1585.	13.7	269
10	Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. <i>Lancet, The</i> , 2011, 378, 693-703.	13.7	264
11	Immediate vs Delayed Intervention for Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 947.	7.4	255
12	Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non- $\sigma$ ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 2016, 134, 906-917.	1.6	246
13	Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1765-74.	7.4	179
14	Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2507.	7.4	175
15	Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 297-308.	27.0	172
16	Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e553-e553.	2.3	159
17	Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. <i>Journal of the American College of Cardiology</i> , 2019, 73, 58-66.	2.8	147
18	Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 552.	7.4	137

#	ARTICLE	IF	CITATIONS
19	Periprocedural myocardial infarction and injury in elective coronary stenting. <i>European Heart Journal</i> , 2018, 39, 1100-1109.	2.2	136
20	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. <i>European Heart Journal</i> , 2012, 33, 1241-1249.	2.2	127
21	Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1676-1685.	2.8	124
22	High Doses of Clopidogrel to Overcome Genetic Resistance. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 392-402.	2.9	118
23	Can We Override Clopidogrel Resistance?. <i>Circulation</i> , 2009, 119, 2854-2857.	1.6	115
24	<i>CYP2C19</i> But Not <i>PON1</i> Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post-Myocardial Infarction Patients. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 422-428.	3.9	110
25	New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1542-1551.	2.8	104
26	P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2016, 116, 369-378.	3.4	97
27	Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose. <i>Circulation</i> , 2008, 118, 1225-1233.	1.6	87
28	Early Aldosterone Blockade in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1917-1927.	2.8	86
29	Long-Term Evolution of Premature Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1868-1878.	2.8	81
30	Impact of Red Blood Cell Transfusion on Platelet Aggregation and Inflammatory Response in Anemic Coronary and Noncoronary Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1289-1296.	2.8	78
31	Coronavirus Disease 2019 Acute Myocarditis and Multisystem Inflammatory Syndrome in Adult Intensive and Cardiac Care Units. <i>Chest</i> , 2021, 159, 657-662.	0.8	78
32	Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. <i>BMJ</i> , The, 2014, 347, g6269-g6269.	6.0	75
33	Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. <i>Lancet</i> , The, 2020, 396, 1737-1744.	13.7	75
34	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2021, 42, 2630-2642.	2.2	69
35	Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. <i>European Heart Journal</i> , 2021, 42, 323-334.	2.2	68
36	Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. <i>European Heart Journal</i> , 2010, 31, 2816-2821.	2.2	62

#	ARTICLE	IF	CITATIONS
37	Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 158-165.	2.9	60
38	Efficacy of Ex Vivo Autologous and In Vivo Platelet Transfusion in the Reversal of P2Y <sub>12</sub> Inhibition by Clopidogrel, Prasugrel, and Ticagrelor. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002786.	3.9	59
39	Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3259-3269.	2.8	55
40	A Direct Comparison of Intravenous Enoxaparin With Unfractionated Heparin in Primary Percutaneous Coronary Intervention (from the ATOLL Trial). <i>American Journal of Cardiology</i> , 2013, 112, 1367-1372.	1.6	54
41	High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization. <i>Circulation</i> , 2014, 129, 2136-2143.	1.6	46
42	Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey. <i>International Journal of Cardiology</i> , 2012, 156, 69-75.	1.7	44
43	Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. <i>American Heart Journal</i> , 2013, 165, 515-522.	2.7	43
44	Prasugrel Monitoring and Bleeding in Real World Patients. <i>American Journal of Cardiology</i> , 2013, 111, 38-44.	1.6	41
45	Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention. <i>Heart</i> , 2018, 104, 767-772.	2.9	41
46	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 225-235.	3.0	40
47	Microparticles and sudden cardiac death due to coronary occlusion. <i>The TIDE (Thrombus and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T</i> 28-36.	1.0	39
48	Pretreatment with P2Y <sub>12</sub> Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy. <i>Circulation</i> , 2014, 130, 1904-1914.	1.6	36
49	Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008481.	3.9	35
50	Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: Insights from the French FAST-MI program over 15years. <i>International Journal of Cardiology</i> , 2014, 177, 281-286.	1.7	33
51	Quantitative flow ratio virtual stenting and post stenting correlations to post stenting fractional flow reserve measurements from the DOCTORS (Does Optical Coherence Tomography Optimize Results) Tj ETQq1 1 0.784314 rgBT /D	1.0	34
52	Dual antiplatelet therapy: optimal timing, management, and duration. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 198-204.	3.0	32
53	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1315-1324.	1.9	31
54	Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 646-656.	2.9	31

#	ARTICLE	IF	CITATIONS
55	Usefulness of Biomarker Strategy to Improve GRACE Score's Prediction Performance in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Low Event Rates. <i>American Journal of Cardiology</i> , 2010, 106, 650-658.	1.6	28
56	Slow Response to Clopidogrel Predicts Low Response. <i>Journal of the American College of Cardiology</i> , 2010, 55, 815-822.	2.8	28
57	Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. <i>International Journal of Cardiology</i> , 2013, 167, 73-79.	1.7	28
58	The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. <i>EuroIntervention</i> , 2018, 14, 78-85.	3.2	28
59	Ticagrelor in the Renal Dysfunction Subgroup: Subjugated or Substantiated?. <i>Circulation</i> , 2010, 122, 1049-1052.	1.6	27
60	Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 182-190.	1.7	27
61	One-year clinical outcomes of the STENTYS Self-Apposing™ coronary stent in patients presenting with ST-segment elevation myocardial infarction: results from the APPOSITION III registry. <i>EuroIntervention</i> , 2015, 11, 264-271.	3.2	26
62	Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVEREST-2/ST-HIV study. <i>European Heart Journal</i> , 2017, 38, ehw583.	2.2	25
63	Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study. <i>International Journal of Cardiology</i> , 2018, 254, 36-42.	1.7	25
64	Thrombus composition in sudden cardiac death from acute myocardial infarction. <i>Resuscitation</i> , 2017, 113, 108-114.	3.0	24
65	Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 104-112.	1.7	23
66	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 173-183.	2.2	23
67	Interleukin-1 $\beta$ and Risk of Premature Death in Patients With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1763-1773.	2.8	23
68	Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Bedside Test. <i>Journal of the American College of Cardiology</i> , 2010, 55, 617-625.	2.8	22
69	2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 324-333.	3.0	22
70	Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. <i>International Journal of Cardiology</i> , 2013, 163, 266-271.	1.7	21
71	Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study. <i>American Heart Journal</i> , 2014, 168, 674-681.e1.	2.7	21
72	Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians. <i>Heart</i> , 2016, 102, 1648-1654.	2.9	21

#	ARTICLE	IF	CITATIONS
73	Contrast-induced nephropathy: the sin of primary percutaneous coronary intervention?. <i>European Heart Journal</i> , 2014, 35, 1504-1506.	2.2	20
74	Updates and Current Recommendations for the Management of Patients With Non-“ST-Elevation Acute Coronary Syndromes: What It Means for Clinical Practice. <i>American Journal of Cardiology</i> , 2015, 115, 10A-22A.	1.6	20
75	Coronary Revascularization in the Diabetic Patient. <i>Circulation</i> , 2014, 130, 918-922.	1.6	19
76	Copeptin as a prognostic biomarker in acute myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 274, 337-341.	1.7	19
77	On- Versus Off-Hours Presentation and Mortality of ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2260-2268.	2.9	18
78	Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 428-436.	1.6	17
79	FXIII-A Leu34 genetic variant in premature coronary artery disease: A genotype “ phenotype case control study. <i>Thrombosis and Haemostasis</i> , 2011, 106, 511-520.	3.4	16
80	Pharmacogenetics of Clopidogrel. <i>Current Pharmaceutical Design</i> , 2012, 18, 5309-5327.	1.9	16
81	Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach. <i>Drugs and Aging</i> , 2019, 36, 531-539.	2.7	16
82	Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2020, 225, 60-68.	2.7	16
83	Do Patients need Lifelong $\beta$ -Blockers after an Uncomplicated Myocardial Infarction?. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 431-438.	2.2	15
84	One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial. <i>Circulation</i> , 2022, 145, 486-488.	1.6	15
85	Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2016, 115, 382-391.	3.4	14
86	Anticoagulation in Acute Coronary Syndrome-State of the Art. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 508-513.	3.1	14
87	Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-“ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 906-914.	2.8	14
88	Clopidogrel resistance: What's new?. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 349-353.	1.6	13
89	Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 95-103.	3.9	13
90	Impact of transfer time on mortality in acute coronary syndrome with ST-segment elevation treated by angioplasty. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 639-648.	1.6	13

#	ARTICLE	IF	CITATIONS
91	One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 604-610.	1.6	11
92	Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PÉPCIT study. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 823-833.	1.7	11
93	An evidence-based review of current anti-platelet options for STEMI patients. <i>International Journal of Cardiology</i> , 2013, 166, 294-303.	1.7	11
94	Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 554-562.	1.6	11
95	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 065-074.	3.4	11
96	Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: The FAST-MI registry. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 347-354.	1.6	10
97	Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1055-1064.	3.4	10
98	Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Angiology</i> , 2017, 68, 29-39.	1.8	10
99	Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as biomarkers of acute kidney injury after ST-segment elevation myocardial infarction treated by percutaneous coronary intervention. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 180-186.	1.6	10
100	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1049-1057.	1.9	9
101	Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial. <i>American Heart Journal</i> , 2015, 170, 778-786.	2.7	9
102	Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 503-511.	2.2	9
103	Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 680.	2.4	9
104	Clinical manifestations and outcomes of coronavirus disease-19 in heart transplant recipients: a multicentre case series with a systematic review and meta-analysis. <i>Transplant International</i> , 2021, 34, 721-731.	1.6	9
105	Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 502-510.	1.6	8
106	Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trial. <i>Clinical Cardiology</i> , 2021, 44, 143-150.	1.8	8
107	Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation. <i>Clinical Cardiology</i> , 2016, 39, 192-200.	1.8	7
108	Selatogrel for Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2598-2601.	2.8	7



#	ARTICLE	IF	CITATIONS
109	Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study. <i>American Heart Journal</i> , 2020, 225, 27-37.	2.7	6
110	Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008296.	3.9	5
111	Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure. <i>Thrombosis and Haemostasis</i> , 2011, 105, 1024-1031.	3.4	4
112	Rapid P2Y <sub>12</sub> Inhibition. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 328-331.	3.9	4
113	Long-Term Secondary Prevention After High-Risk Stenting. <i>Circulation</i> , 2015, 131, 13-16.	1.6	4
114	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 43-53.	2.2	4
115	Modulation of cholesterol efflux capacity in patients with myocardial infarction. <i>Current Opinion in Cardiology</i> , 2019, 34, 714-720.	1.8	4
116	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial. <i>Chest</i> , 2021, 159, 1415-1425.	0.8	4
117	Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 681-691.	2.2	4
118	Impact of age on the effect of pre-hospital P2Y <sub>12</sub> receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis. <i>EuroIntervention</i> , 2018, 14, 789-797.	3.2	4
119	One-Year Clinical Outcomes of Patients Presenting With ST-Segment Elevation Myocardial Infarction Caused by Bifurcation Culprit Lesions Treated With the Stentys Self-Apposing Coronary Stent: Results From the APPOSITION III Study. <i>Journal of Invasive Cardiology</i> , 2017, 29, 253-258.	0.4	4
120	Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analyses. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2023, 9, 194-202.	4.0	4
121	Anticoagulant for primary percutaneous coronary intervention – the last dance for unfractionated heparin?. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 259-261.	1.6	3
122	Potent P2Y <sub>12</sub> Inhibitors in Low-Risk Patients. <i>Journal of the American College of Cardiology</i> , 2016, 67, 614-617.	2.8	3
123	New Insights for Low Dosing With the New P2Y <sub>12</sub> Inhibitors. <i>Circulation Journal</i> , 2014, 78, 2840-2842.	1.6	2
124	Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction in Nonagenarians: A Multicenter Study. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 384-386.	2.6	2
125	Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007749.	3.9	2
126	Kidney in the transformation matrix. <i>European Heart Journal</i> , 2019, 40, 1233-1235.	2.2	2



#	ARTICLE	IF	CITATIONS
127	Appropriate criteria for the definition of Type 4a MI. European Heart Journal, 2021, , .	2.2	2
128	Antiplatelet options for secondary prevention in acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2011, 9, 1403-1415.	1.5	1
129	Reply. Journal of the American College of Cardiology, 2014, 63, 2588-2589.	2.8	1
130	Pretreatment with P2Y12 inhibitors in non-â€“ST-segment elevation acute coronary syndrome: Time to revise the guidelines?. Archives of Cardiovascular Diseases, 2014, 107, 1-3.	1.6	1
131	Platelet Function Test-â€“Guided Strategy. Circulation: Cardiovascular Interventions, 2015, 8, e002716.	3.9	1
132	Cangrelor. JACC: Cardiovascular Interventions, 2016, 9, 1914-1916.	2.9	1
133	Premature coronary artery disease. Sang Thrombose Vaisseaux, 2012, 24, 173-182.	0.1	0
134	TCT-138 Clopidogrel Pretreatment in Non ST Elevation Acute Coronary Syndroms: no effect on mortality, decrease in ischemic endpoints at a price of more major bleeding.. Journal of the American College of Cardiology, 2013, 62, B44.	2.8	0
135	Assessment of the Anticoagulation Activity of Apixaban-â€“â€“ Reply -â€“. Circulation Journal, 2015, 79, 1642.	1.6	0
136	EVALUATION OF INTRACORONARY THROMBUS BY OPTICAL COHERENCE TOMOGRAPHY (OCT): CHARACTERIZATION, QUANTIFICATION AND PROGNOSTIC IMPACT IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME - A DOCTORS SUBSTUDY. Journal of the American College of Cardiology, 2018, 71, A1182.	2.8	0
137	Reply. Journal of the American College of Cardiology, 2020, 76, 486-487.	2.8	0
138	Oral Antiplatelet Therapy. , 2010, , 73-82.		0